Schott Pharma Stock - RBC reiterates Sector Perform rating and EUR 18 target

Schott Pharma stock faces a fresh analyst check: RBC Capital Markets has reiterated its Sector Perform rating and EUR 18 price target, while the Wednesday focus falls on the company’s operations, order book and role in drug-delivery systems.

Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 17:05 CET. Details in the imprint.

Schott Pharma (DE000A3ENQ51) received a fresh look from RBC Capital Markets on 06/17/2026. The analyst house reiterated a Sector Perform rating and kept its EUR 18.00 price target, according to a dpa-AFX summary of the RBC note.

RBC’s neutral stance and target

According to the dpa-AFX report, RBC analyst Charles Weston kept his Sector Perform stance on Schott Pharma, effectively a neutral view within the coverage universe. The price target remains EUR 18.00, only modestly above the latest quoted level around EUR 17.

Finanzen.net data show the implied upside from the target at roughly 5-6% versus a recent spot price in the mid-EUR 17 range. MarketScreener also flags the RBC view as Neutral, mirroring the Sector Perform language and the unchanged target.

Operations and strategic positioning

Schott Pharma focuses on primary pharmaceutical packaging and drug-delivery systems such as prefillable syringes, cartridges and vials for injectable medicines. The group emphasizes solutions for biologics and high-value drugs, a segment benefiting from structurally growing demand in many therapy areas.

In early June, Schott Pharma highlighted its SmartGuard Auto-Injector Case accessory, which is designed to work with various auto-injectors and support self-injection trends. The company positions such add-ons as a way to deepen ties with pharma customers by offering more integrated solutions around drug delivery.

How the company makes money

Schott Pharma generates revenue by supplying glass and polymer primary packaging, syringes and related systems to pharmaceutical manufacturers worldwide. Its business model is largely B2B, with long-standing customer relationships and qualification cycles that can support relatively stable demand over time.

Where the stock trades today

The shares of Schott Pharma (DE000A3ENQ51) trade on Xetra at EUR 17.18 as of 06/17/2026, 16:50 CET.

Schott Pharma at a glance

• Company: SCHOTT Pharma AG & Co. KGaA
• ISIN: DE000A3ENQ51
• WKN: A3ENQ5
• Ticker: 1SXP
• Venue: Xetra
• Price (as of 06/17/2026, 16:50 CET): 17.18 EUR
• Market cap: 3,000,000,000 EUR (as of 06/17/2026)
• Sector / Industry: Health Care - Pharmaceuticals & Medical Packaging
• Index membership: SDAX
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.